Korro Bio Inc
KRRO
查看详细走势图
12.570USD
+1.030+8.93%
收盘 02/06, 16:00（美东）报价延迟15分钟
118.13M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+8.93%
5天
-5.70%
1月
+48.06%
6月
-20.74%
今年开始到现在
+56.93%
1年
-63.69%
查看详细走势图
TradingKey Korro Bio Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Korro Bio Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值低估，在生物技术与医疗研究行业排名99/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价17.57。中期看，股价处于下降通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Korro Bio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Korro Bio Inc亮点
亮点风险
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
业绩增长期
公司处于发展阶段，最新年度总收入2.27M美元
利润高增长
公司净利润处于行业前列，最新年度总收入2.27M美元
估值高估
公司最新PE估值-1.33，处于3年历史高位
机构加仓
最新机构持股11.02M股，环比增加9.18%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值7.18K
分析师目标
根据
10
位分析师
买入
评级
17.000
目标均价
+38.66%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Korro Bio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Korro Bio Inc简介
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
公司代码KRRO
公司Korro Bio Inc
CEODr. Ram Aiyar, Ph.D.
网址https://www.korrobio.com/
相关品种
